Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm

D'Nyce L. Williams, Daniel R. Newman, Susan A. Ballagh, Mitchell D Creinin, Kurt Barnhart, Debra H. Weiner, April J. Bell, Denise J. Jamieson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN: Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS: Sixty-nine participants (85%) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS: Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.

Original languageEnglish (US)
Pages (from-to)977-984
Number of pages8
JournalSexually Transmitted Diseases
Volume34
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Foams and Jellies Vaginal Creams
Anti-Infective Agents
Diaphragm
Safety
Colposcopy
Physical Examination
BufferGel
K-Y jelly

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)

Cite this

Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm. / Williams, D'Nyce L.; Newman, Daniel R.; Ballagh, Susan A.; Creinin, Mitchell D; Barnhart, Kurt; Weiner, Debra H.; Bell, April J.; Jamieson, Denise J.

In: Sexually Transmitted Diseases, Vol. 34, No. 12, 12.2007, p. 977-984.

Research output: Contribution to journalArticle

Williams, D'Nyce L. ; Newman, Daniel R. ; Ballagh, Susan A. ; Creinin, Mitchell D ; Barnhart, Kurt ; Weiner, Debra H. ; Bell, April J. ; Jamieson, Denise J. / Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm. In: Sexually Transmitted Diseases. 2007 ; Vol. 34, No. 12. pp. 977-984.
@article{e5bd8ad5c35f438eaac3be07fefa82f6,
title = "Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm",
abstract = "OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN: Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS: Sixty-nine participants (85{\%}) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS: Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.",
author = "Williams, {D'Nyce L.} and Newman, {Daniel R.} and Ballagh, {Susan A.} and Creinin, {Mitchell D} and Kurt Barnhart and Weiner, {Debra H.} and Bell, {April J.} and Jamieson, {Denise J.}",
year = "2007",
month = "12",
doi = "10.1097/OLQ.0b013e31813347e9",
language = "English (US)",
volume = "34",
pages = "977--984",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm

AU - Williams, D'Nyce L.

AU - Newman, Daniel R.

AU - Ballagh, Susan A.

AU - Creinin, Mitchell D

AU - Barnhart, Kurt

AU - Weiner, Debra H.

AU - Bell, April J.

AU - Jamieson, Denise J.

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN: Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS: Sixty-nine participants (85%) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS: Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.

AB - OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN: Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS: Sixty-nine participants (85%) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS: Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.

UR - http://www.scopus.com/inward/record.url?scp=36349021921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349021921&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e31813347e9

DO - 10.1097/OLQ.0b013e31813347e9

M3 - Article

C2 - 18080349

AN - SCOPUS:36349021921

VL - 34

SP - 977

EP - 984

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 12

ER -